Is Mounjaro FDA Approved for Weight Loss?
Mounjaro (tirzepatide) is FDA approved for type 2 diabetes management in adults, with or without cardiovascular disease, at doses up to 15 mg weekly via subcutaneous injection.[1] Approval came in May 2022. It is not approved for weight loss or obesity treatment.
Why Only Diabetes Right Now?
The FDA label specifies glycemic control, cardiovascular risk reduction, and lowering risks of kidney disease progression, heart attack, stroke, or CV death in relevant patients.[1] Weight loss occurs as a side effect—clinical trials showed 15-22% average body weight reduction over 72 weeks—but the agency has not greenlit it as a primary weight loss indication.[2]
What About the Weight Loss Version?
Eli Lilly markets Zepbound (same active ingredient, tirzepatide) separately for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition like hypertension or type 2 diabetes. Zepbound gained FDA approval in November 2023.[3] Dosing and administration mirror Mounjaro, but indications differ.
How Do Mounjaro and Zepbound Compare?
| Aspect | Mounjaro | Zepbound |
|-----------------|-----------------------------------|-----------------------------------|
| Primary Use | Type 2 diabetes | Obesity/overweight management |
| FDA Approval| May 2022 | November 2023 |
| Max Dose | 15 mg weekly | 15 mg weekly |
| Boxed Warning| Thyroid C-cell tumor risk | Same |
| Cost (approx., 4-week supply) | $1,000-$1,300 (list price) | Similar |
Both carry risks like gastrointestinal issues, pancreatitis, and gallbladder problems. Off-label Mounjaro use for weight loss is common but lacks formal approval, potentially affecting insurance coverage.[2][4]
When Might Mounjaro Get Weight Loss Approval?
No timeline exists; Eli Lilly focuses Zepbound on that market. Patent exclusivity for tirzepatide runs through 2036, with extensions possible, per DrugPatentWatch.com.[5] Challenges from competitors like Novo Nordisk could influence future labeling expansions.
Sources
[1] FDA Label: Mounjaro
[2] NEJM: SURMOUNT-1 Trial
[3] FDA Approval: Zepbound
[4] ADA Standards of Care 2024
[5] DrugPatentWatch: Tirzepatide Patents